STOCK TITAN

Cytodyn Inc - CYDY STOCK NEWS

Welcome to our dedicated news page for Cytodyn (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cytodyn's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cytodyn's position in the market.

Rhea-AI Summary
CytoDyn Inc. announces FDA lifting the clinical hold on leronlimab for HIV clinical trial. CEO Dr. Jacob Lalezari to host webcast for company update on March 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.64%
Tags
none
-
Rhea-AI Summary
CytoDyn Inc. (CYDY) has submitted a revised HIV clinical trial protocol to the FDA, aiming to remove the clinical hold currently in effect. The company's CEO, Dr. Jacob Lalezari, highlighted the potential of leronlimab in addressing increased inflammation and immune activation in HIV patients, with implications for heart attacks, strokes, and other vascular events. Additionally, CytoDyn's research partnership with Albert Einstein College of Medicine and Montefiore Medical Center is progressing with a pre-clinical trial for studying leronlimab in glioblastoma, a common and often untreatable form of primary brain cancer, with preparations underway for a trial in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
-
Rhea-AI Summary
CytoDyn Inc. announced the appointment of Dr. Jacob Lalezari as CEO and Mitchell Cohen as interim CFO. Dr. Lalezari's appointment follows a competitive search process, and he expressed optimism about the company's clinical protocol in HIV+ subjects. The company also expressed confidence in Mr. Cohen's ability to lead financial operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
management
Rhea-AI Summary
CytoDyn Inc. (CYDY) to host an investment community webcast on December 14, 2023, to provide a Company update on leronlimab, a potential CCR5 antagonist with multiple therapeutic indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.33%
Tags
none
-
Rhea-AI Summary
CytoDyn Inc. (CYDY) appoints Dr. Jacob Lalezari as interim CEO. Dr. Lalezari brings 34 years of industry experience and will lead corporate and product development, focusing on short-term clinical development and fundraising. His extensive experience in clinical studies of viral diseases makes him a valuable addition to the company's leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
management
-
News
Rhea-AI Summary
CytoDyn Inc. provides an update on its progress in developing leronlimab for multiple therapeutic indications. The company has faced delays in satisfying the FDA's clinical hold submission requirements, but has gained new insights and engaged with key opinion leaders in the HIV treatment field. CytoDyn has implemented cost-cutting measures and is focused on resolving the clinical hold and strengthening its leadership team. The company is also exploring potential indications for leronlimab and is involved in ongoing litigation. Shareholders are encouraged to vote on increasing the total number of authorized shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.58%
Tags
Cytodyn Inc

OTC:CYDY

CYDY Rankings

CYDY Stock Data

154.27M
966.31M
0.81%
0.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Vancouver

About CYDY

retired ceo